Coated Tablet Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Coated tablet plant sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹4.3 crore - ₹76 crore CapEx this DPR captures:

• Plant Master File (PMF) and Site Master File (SMF) for export dossier
• NABL accreditation for QC lab, BSL-2/BSL-3 containment certification where applicable
• Bio-medical waste authorisation under BMW Rules 2016
• PLI Bulk Drugs (₹15,000 cr) or PLI Medical Devices (₹3,420 cr) participation
• NABH / NABL accreditation if the project includes a clinical or diagnostic arm
• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)
• CDSCO + State Drug Controller dual approval for new formulations

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>India's pharmaceutical sector represents a cornerstone of the national economy, with the coated tablet segment operating within the larger oral solid dosage (OSD) manufacturing ecosystem. The Asia-Pacific region commands approximately 36% of the global market share for tablet coating, with India serving as a primary growth engine alongside China. The sector is characterized by a dual structure: an organized segment comprising large-scale, automated, regulatory-compliant facilities (US FDA, WHO-GMP certified) dominated by major players like Sun Pharmaceutical Industries Ltd., Dr.

Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, and Aurobindo Pharma Limited, and a semi-organized segment serving domestic markets with varying compliance standards.</p><p>The industrial machinery segment supporting coated tablet production remains predominantly domestic, with Indian manufacturers supplying approximately 70% to 75% of total pharmaceutical machinery requirements, while imported machinery commands roughly 25% to 30% of the market, primarily utilized by large-scale export-oriented units demanding specialized high-end specifications. Key domestic equipment suppliers include Cadmach Machinery and Cijen Pharma Machinery Private Limited (Ahmedabad, Gujarat), alongside established giants ACG and Gansons Limited. The raw material supply chain presents significant scale, with the Active Pharmaceutical Ingredients (API) market valued at USD 245.67 billion in 2026 and the pharmaceutical excipients market reaching USD 9.86 billion in 2026, though API exporter gross margins have contracted to 18, 22% in 2025 from 26, 30% in 2020.</p><p>Manufacturing capabilities within India demonstrate substantial scale potential.

For instance, Tablets India operates facilities in Chennai, Pondicherry, and Himachal Pradesh with tablet production capacity of 350 million tablets per annum and sugar coating capacity of 0.5 million tablets daily, while Taj Pharma India Ltd's Sarigam GIDC facility in Gujarat maintains oral solid dosage tablet manufacturing capacity of 120 million tablets monthly. The sector is witnessing a technological paradigm shift from traditional sugar coating to film coating systems, with continuous manufacturing integration replacing batch processes to enhance efficiency and reduce cycle times.</p>

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

<p>The technological landscape of coated tablet manufacturing is undergoing rapid transformation, shifting decisively from traditional batch pan coating systems to continuous flow manufacturing systems that offer enhanced process control and reduced cycle times. Modern coating facilities require sophisticated Air Handling Unit (AHU) heat recovery systems capable of reclaiming 25% to 35% of thermal energy from exhaust streams without air mixing, addressing the fact that granulation and tablet coating account for 60% to 70% of total utility consumption in Oral Solid Dosage (OSD) manufacturing lines. Advanced facilities integrate optimized anti-bearding spray guns and automated control systems to minimize downtime and reduce rework.</p><p>Capital equipment options span multiple technology tiers, from basic small-scale conventional tablet coating machines priced between ₹1,50,000 to ₹3,50,000 (capacities of 10 kg to 100 kg pans) to mid-range automatic tablet coaters at ₹5,00,000 to ₹12,00,000, up to advanced cGMP fully automatic systems commanding significantly higher investments.

The technology mix must accommodate both film coating (increasingly dominant for its efficiency) and sugar coating capabilities, with the latter requiring substantial specialized operator training compared to film coating processes.</p><p>Digitalization presents both opportunity and challenge; while legacy equipment suffers unplanned downtime rates of 15% to 20% and manual batch record completion requires 40 to 80 hours per batch, technology transfer delays can cost over USD 1 million per month in deferred revenue. Modern plants increasingly integrate continuous manufacturing lines that reduce manual validation timelines (traditionally extending 30 to 60 days) and mitigate quality assurance staff turnover impacts (currently 22% to 28% annually). Leading suppliers like ACG provide integrated solid-dosage manufacturing equipment with advanced coating systems, while material science innovations from companies like Ashland (Aquarius film coating systems) and Colorcon drive formulation advancements requiring compatible machinery specifications.</p>

For the Coated Tablet Plant falling within the ₹4.3 crore to ₹76 crore CapEx band, we recommend a debt-equity structure of 70:30 for facilities below ₹15 crore capital cost, leveraging CGTMSE guarantee coverage for SME lending, with equity contribution allocated between promoter capital and PMEGP subsidy for greenfield projects with project cost below ₹2 crore in plant and machinery. Medium and large-scale facilities should target 65:35 debt-equity leveraging priority sector lending classification under RBI guidelines for pharmaceutical manufacturing. Primary lending institutions should include SIDBI for term loan access under its pharmaceutical refinance window, alongside commercial bank relationships with SBI, HDFC Bank, and Axis Bank which maintain dedicated pharmaceutical MSME desks with expedited processing. The PLI Scheme for Bulk Drugs and Medical Devices offers 5-10% production-linked incentives on incremental sales for in-scope Active Pharmaceutical Ingredients, while state-level incentives from Gujarat, Maharashtra, and Telangana include land subsidies, electricity duty exemption, and stamp duty relaxation for pharma park installations. Working capital requirements for pharmaceutical tablet manufacturing typically span 75-90 days in the receivables cycle given hospital and distributor channel payment terms, with raw material inventory averaging 45-60 days covering API, excipients, and packaging materials. Inventory carrying costs of 12-15% annually should be factored into facility-level working capital planning. Letter of credit facilities for API imports from China and Europe require 90-180 day tenures with foreign exchange hedging through forward contracts given rupee volatility against USD and CNY. Project IRR benchmarks of 22-28% are achievable for well-positioned facilities serving chronic therapy segments with stable product portfolios.

<p>Despite favorable growth projections, the coated tablet plant business in India faces significant operational and market risks. Margin compression represents a critical challenge, with API exporter gross margins contracting to 18, 22% in 2025 from 26, 30% in 2020, and average U.S. generic drug prices decreasing by 37% between 2020 and 2025, placing downward pressure on manufacturing service fees and tablet pricing. The capital intensity of establishing compliant facilities ranges from ₹5 Crores for basic small-scale units to over ₹250 Crores for large multi-line plants, creating substantial financial risk if capacity utilization fails to reach breakeven thresholds amid aggressive capacity additions by competitors like Sun Pharmaceutical.</p><p>Operational risks include high utility costs, with granulation and tablet coating consuming 60% to 70% of total OSD manufacturing energy, potentially eroding the 35% to 40% gross margins if energy recovery systems are not implemented.

Quality assurance challenges manifest in manual batch record requirements consuming 40 to 80 hours per batch, technology transfer delays costing over USD 1 million monthly in deferred revenue, and validation timeline extensions of 30 to 60 days. Workforce risks are pronounced, with quality assurance staff turnover rates of 22% to 28% annually and sugar coating operations requiring substantial specialized training that may be disrupted by evolving regulatory mandates requiring 60% of skilled workers to be formal apprenticeship graduates by 2026.</p><p>Regulatory compliance risks center on strict Schedule M GMP requirements mandating specific area allocations (minimum 30 square meters for coating sections) and equipment standards enforced by CDSCO and State Licensing Authorities. Failure to maintain compliance risks license suspension and market exclusion.

Import dependency risks persist for the 25% to 30% of high-end specialized machinery sourced internationally, exposing operators to currency fluctuations and supply chain disruptions. Competitive intensity from established players with economies of scale, such as the Rs 3,000 crore expansion by Sun Pharmaceutical and Ashland's new Ambernath facility, could trigger price wars or capacity gluts in specific regional clusters like Gujarat and Maharashtra. Finally, technological obsolescence risks require continuous reinvestment as the industry shifts from batch to continuous manufacturing, potentially stranding investments in conventional pan coating equipment priced between ₹1,50,000 to ₹3,50,000 that lack automation capabilities.</p>